Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198747 | 0.86 | KMT2A (0.49) | ALDH1A1HPGDKDM4EKMT2AGAA | |
| SCHEMBL8874118 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HPGDKDM4EKMT2AGAA | |
| Hydrochloric Acid SCHEMBL30496734 | 0.83 | KMT2A (0.47) | ALDH1A1HPGDKDM4EKMT2AGAA | |
| SCHEMBL7428611 | 0.82 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EKMT2AGAA | |
| SCHEMBL24211765 | 0.81 | HPGD (0.44) | ALDH1A1HPGDKDM4EKMT2AGAA | |
| SCHEMBL10310457 | 0.81 | TAAR1 (0.50) | ALDH1A1HPGDKDM4EKMT2AHTT | |
| SCHEMBL30496716 | 0.81 | TAAR1 (0.50) | ALDH1A1HPGDKDM4EKMT2AHTT | |
| SCHEMBL5523322 | 0.81 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EKMT2AGAA | |
| SCHEMBL1244426 | 0.81 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4EKMT2AGAA | |
| SCHEMBL12139528 | 0.81 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4EKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2009089053-A1 | OLIGOMER-GUANIDINE CLASS CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-07-16 | — | — | WO | claimed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110160163-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | US | disclosed |
| US-20090203702-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203702-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009089053-A1 | OLIGOMER-GUANIDINE CLASS CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-07-16 | — | — | WO | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205305-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070060572-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060572-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160163-A1 | INHIBITORS OF p38 | ZAP70, MAPK1, MAP3K20 | ALDH1A1 3654/4885HPGD 2180/4885KDM4E 2410/4885 |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | ALDH1A1 4635/4885HPGD 2441/4885KDM4E 1371/4885 |
| US-20090203702-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | ALDH1A1 3189/4885HPGD 1371/4885KDM4E 3426/4885 |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | ALDH1A1 1471/4885HPGD 507/4885KDM4E 659/4885 |
| US-20070060572-A1 | Inhibitors of p38 | MAPK1, MAPK3, MAP3K1 | ALDH1A1 3189/4885HPGD 1371/4885KDM4E 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.